Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 15/20 | 0.67 |
| ▸ | IKZF1 | Q13422 | 5/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24320104 | 0.92 | IKZF1 (0.71) | IKZF2IKZF1 | |
| SCHEMBL24320753 | 0.91 | IKZF2 (0.68) | IKZF2IKZF1 | |
| Hydrochloric Acid SCHEMBL29582960 | 0.90 | IKZF2 (0.67) | IKZF2IKZF1 | |
| SCHEMBL24320751 | 0.83 | IKZF1 (0.72) | IKZF2IKZF1 | |
| Hydrochloric Acid SCHEMBL29583984 | 0.82 | IKZF1 (0.71) | IKZF2IKZF1 | |
| SCHEMBL20765336 | 0.82 | IKZF2 (0.80) | IKZF2IKZF1 | |
| SCHEMBL30368945 | 0.82 | IKZF2 (0.80) | IKZF2IKZF1 | |
| SCHEMBL21340264 | 0.81 | IKZF2 (0.70) | IKZF2IKZF1 | |
| SCHEMBL30326445 | 0.81 | IKZF2 (0.70) | IKZF2IKZF1 | |
| SCHEMBL22345896 | 0.81 | IKZF2 (1.00) | IKZF2IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228651-A1 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081976-A1 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081976-A1 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |